Recent reports have established atherosclerosis (AS) as a major factor in the pathogenetic process of cardiovascular diseases such as ischemic stroke and coronary heart disease. Although the possible pathogenesis of AS remains to be elucidated, a large number of investigations strongly suggest that the inhibition of toll-like receptors (TLRs) alleviates the severity of AS to some extent by suppressing vascular inflammation and the formation of atherosclerotic plaques. As pattern recognition receptors, TLRs occupy a vital position in innate immunity, mediating various signaling pathways in infective and sterile inflammation. This review summarizes the available data on the research progress of AS and the latest antiatherosclerotic drugs associated with TLR pathway.
*Department of Physiology, State Key Laboratory of Natural Medicines, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China; and
†Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Reprints: Yun-Man Li or Ya-Hui Hu (e-mail: email@example.com or firstname.lastname@example.org).
The work described in this article was supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Thirteenth Five-year Plan Period (No. 2016ZX09101031) and the “Double First-Class” Construction Technology Innovation Team Project of China Pharmaceutical University (No. CPU2018GY23).
The authors report no conflicts of interest.
Received January 17, 2019
Accepted July 30, 2019